Abstract：Objective To study the effects of hemoperfusion treatment on serum interleukin-17 (IL-17) and IL-23 levels in children with Henoch-Schönlein purpura (HSP). Methods Eighty-seven children who were diagnosed with HSP and who had received hemoperfusion treatment between January 2011 and December 2012 were enrolled. Twenty-seven sex- and age-matched healthy children were recruited as normal controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of IL-17 and IL-23. Results The serum IL-23 and IL-17 levels in the HSP group were significantly higher than in the control group (P< 0.05). After hemoperfusion treatment, the serum IL-23 and IL-17 levels in the HSP group were significantly reduced to the levels of the control group. Serum serum IL-17 level was positively correlated with serum IL-23 level (P< 0.05) in children with HSP. Conclusions Hemoperfusion treatment can reduce serum IL-23 and IL-17 levels in children with HSP, suggesting that the treatment may be effective for HSP.
LIU Li,HUANG Yan-Ping,FANG Xia-Ling et al. Effects of hemoperfusion treatment on serum IL-23 and IL-17 levels in children with Henoch-Schönlein purpure[J]. CJCP, 2015, 17(8): 796-799.
Hamdan JM, Barqawi MA. Henoch -Schönlein purpura in children: influence of age on the incidence of nephritis and arthritis[J]. Saudi Med J, 2008, 29(4): 549-552.
[2]
Gardenrmedwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins[J]. Lancet, 2002, 360(9341): 1197-1202.
[3]
Chen O, Zhu XB, Ren H, et al. The imbalance of Th17/Treg in Chinese children with Henoch-Schönlein purpura[J]. Int Immunopharmacol, 2013, 16(1): 67-71.
[4]
Jen HY, Chuang YH, Lin SC, et al. Increased serum interleukin-17 and peripheral Th17 cells in children with acute Henoch-Schönlein purpura[J]. Psdiatr Allergy Immunol, 2011, 22(8): 862-868.
[5]
Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases[J]. Clin Dev Immunol, 2013, 2013: 968549.
[6]
Nakajima K. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis[J]. J Dermatol, 2012, 39(3): 219-224.
Brentano F, Ospelt C, Stanczyk J, et al. Abundant expression of the interleukin (IL) 23 subunit p19, but low levels of bioactive IL23 in the rheumatoidsynovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis[J]. Ann Rheum Dis, 2009, 68(1): 143-150.
[9]
Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cell in systemic lupus erythematosus[J]. Clin Immunol, 2014, 154(1): 1-12.
[10]
Leonardi S, Cuppari C, Manti S, et al. Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome(AEDS): association with clinical severity and phenotype[J]. Allergy Asthma Proc, 2015, 36(1): 74-81.
[11]
Li Y, Hua S. Mechanisms of pathogenesis in allergic asthma: role of interleukin-23[J]. Respirology, 2014, 19(5): 663-669.
